These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 15220241)

  • 1. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
    Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
    Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
    Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
    J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
    Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
    Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).
    Wilcox R; Bousser MG; Betteridge DJ; Schernthaner G; Pirags V; Kupfer S; Dormandy J;
    Stroke; 2007 Mar; 38(3):865-73. PubMed ID: 17290029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].
    Kawamori R
    Nihon Rinsho; 2010 Feb; 68(2):235-41. PubMed ID: 20158090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
    Erdmann E; Harding S; Lam H; Perez A
    Diabetes Obes Metab; 2016 Mar; 18(3):266-73. PubMed ID: 26592506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Observational follow-up of the PROactive study: a 6-year update.
    Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
    Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
    Erdmann E; Charbonnel B; Wilcox RG; Skene AM; Massi-Benedetti M; Yates J; Tan M; Spanheimer R; Standl E; Dormandy JA;
    Diabetes Care; 2007 Nov; 30(11):2773-8. PubMed ID: 17666462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity.
    Kaku K; Daida H; Kashiwagi A; Yamashina A; Yamazaki T; Momomura S; Iwase T; Yamasaki Y; Nagatsuka K; Kitagawa K; Kawamori R
    Curr Med Res Opin; 2009 Dec; 25(12):2925-32. PubMed ID: 19835463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes.
    Pratley RE
    Curr Diab Rep; 2006 Feb; 6(1):45-6. PubMed ID: 16522280
    [No Abstract]   [Full Text] [Related]  

  • 13. [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].
    Scheen AJ; Lefèbvre PJ
    Rev Med Liege; 2005 Nov; 60(11):896-901. PubMed ID: 16402538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
    Erdmann E; Dormandy J; Wilcox R; Massi-Benedetti M; Charbonnel B
    Vasc Health Risk Manag; 2007; 3(4):355-70. PubMed ID: 17969365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).
    Charbonnel B; DeFronzo R; Davidson J; Schmitz O; Birkeland K; Pirags V; Scheen A;
    J Clin Endocrinol Metab; 2010 May; 95(5):2163-71. PubMed ID: 20237169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Macrovascular secondary prevention with pioglitazone in diabetics. PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events)].
    Nitschmann S
    Internist (Berl); 2007 Jan; 48(1):89-90; discussion 90-1. PubMed ID: 17187243
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.
    Dormandy J; Bhattacharya M; van Troostenburg de Bruyn AR;
    Drug Saf; 2009; 32(3):187-202. PubMed ID: 19338377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.